HAART

Question 0

Protease inhibitors: mechanism

Answer 0

Block protease in progeny virions

Question 1

-navirs: type

Answer 1

Protease inhibitor

Question 2

Protease inhibitors: toxicities (4)

Answer 2

GI intolerance
Hyperglycemia
Lipodystrophy
Thrombocytopenia (indinavir)

Question 3

Zidovudine: type

Answer 3

NRTI

Question 4

Didanosine: type

Answer 4

NRTI

Question 5

Zalcitabine: type

Answer 5

NRTI

Question 6

Stavudine: type

Answer 6

NRTI

Question 7

Lamivudine: type

Answer 7

NRTI

Question 8

Abacavir: type

Answer 8

NRTI

Question 9

Nevirapine: type

Answer 9

NNRTI

Question 10

Etavirenz: type

Answer 10

NNRTI

Question 11

Delavirdine: type

Answer 11

NNRTI

Question 12

RTIs: mechanism

Answer 12

Preferentially inhibit reverse transcriptase of HIV, prevent incorporation of DNA copy of viral genome into host DNA

Question 13

RTIs: toxicities (5)

Answer 13

Bone marrow suppression
Peripheral neuropathy
Lactic acidosis (NRTIs)
Rash (NNRTIs)
Megaloblastic anemia (ZDV)

Question 14

Enfuvirtide: type

Answer 14

Fusion inhibitor

Question 15

Enfuvirtide: mechanism

Answer 15

bind viral gp41 subunit, inhibit conformational change required for fusion with CD4 cells

Question 16

Enfuvirtide: toxicities (3)

Answer 16

hypersensitivity reactions
reactions at subcutaneous injection site
increased risk of bacterial pneumonia

Question 17

Enfuvirtide: clinical use

Answer 17

In patients who don’t respond to other antiretrovirals